Seroatlas · Human Serome Atlas

GFM2

Ribosome-releasing factor 2, mitochondrial

Also known as: EF-G2mt, EFG2, FLJ21661, RRF2M_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q969S9
Gene
GFM2
Ensembl
ENSG00000164347
Chromosome
5
Canonical length
779 aa
Protein class
Disease related genes, Human disease related genes, Metabolic proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Midbody ring,Mitochondria

OverviewNCBI Gene

Eukaryotes contain two protein translational systems, one in the cytoplasm and one in the mitochondria. Mitochondrial translation is crucial for maintaining mitochondrial function and mutations in this system lead to a breakdown in the respiratory chain-oxidative phosphorylation system and to impaired maintenance of mitochondrial DNA. This gene encodes one of the mitochondrial translation elongation factors, which is a GTPase that plays a role at the termination of mitochondrial translation by mediating the disassembly of ribosomes from messenger RNA . Its role in the regulation of normal mitochondrial function and in disease states attributed to mitochondrial dysfunction is not known. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2013]

Canonical amino-acid sequenceUniProt

779 residues, UniProt reviewed canonical sequence.

>Q969S9|GFM2
     1  MLTNLRIFAM SHQTIPSVYI NNICCYKIRA SLKRLKPHVP LGRNCSSLPG LIGNDIKSLH
    61  SIINPPIAKI RNIGIMAHID AGKTTTTERI LYYSGYTRSL GDVDDGDTVT DFMAQERERG
   121  ITIQSAAVTF DWKGYRVNLI DTPGHVDFTL EVERCLRVLD GAVAVFDASA GVEAQTLTVW
   181  RQADKHNIPR ICFLNKMDKT GASFKYAVES IREKLKAKPL LLQLPIGEAK TFKGVVDVVM
   241  KEKLLWNCNS NDGKDFERKP LLEMNDPELL KETTEARNAL IEQVADLDDE FADLVLEEFS
   301  ENFDLLPAEK LQTAIHRVTL AQTAVPVLCG SALKNKGIQP LLDAVTMYLP SPEERNYEFL
   361  QWYKDDLCAL AFKVLHDKQR GPLVFMRIYS GTIKPQLAIH NINGNCTERI SRLLLPFADQ
   421  HVEIPSLTAG NIALTVGLKH TATGDTIVSS KSSALAAARR AEREGEKKHR QNNEAERLLL
   481  AGVEIPEPVF FCTIEPPSLS KQPDLEHALK CLQREDPSLK VRLDPDSGQT VLCGMGELHI
   541  EIIHDRIKRE YGLETYLGPL QVAYRETILN SVRATDTLDR TLGDKRHLVT VEVEARPIET
   601  SSVMPVIEFE YAESINEGLL KVSQEAIENG IHSACLQGPL LGSPIQDVAI TLHSLTIHPG
   661  TSTTMISACV SRCVQKALKK ADKQVLEPLM NLEVTVARDY LSPVLADLAQ RRGNIQEIQT
   721  RQDNKVVIGF VPLAEIMGYS TVLRTLTSGS ATFALELSTY QAMNPQDQNT LLNRRSGLT

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GFM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.28
Highest tissue expression
36 nTPM

Expression across tissuesHPA

Tissue

  • tongue: 36 nTPM
  • liver: 32 nTPM
  • heart muscle: 31 nTPM
  • skeletal muscle: 29 nTPM
  • parathyroid gland: 29 nTPM
  • fallopian tube: 22 nTPM

Single-cell type

  • fallopian tube ciliated cells: 98 nCPM
  • endometrial ciliated cells: 81 nCPM
  • respiratory ciliated cells: 62 nCPM
  • parietal cells: 57 nCPM
  • sertoli cells: 54 nCPM
  • foveolar cells: 54 nCPM

Immune cell

  • basophil: 23 nTPM
  • NK-cell: 16 nTPM
  • non-classical monocyte: 12 nTPM
  • eosinophil: 9.2 nTPM
  • memory B-cell: 8.3 nTPM
  • memory CD8 T-cell: 7.5 nTPM

Brain region

  • choroid plexus: 37 nTPM
  • cerebral cortex: 26 nTPM
  • hypothalamus: 25 nTPM
  • white matter: 24 nTPM
  • basal ganglia: 24 nTPM
  • pons: 24 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about GFM2.

Disease | AllUniProt

Conditions GFM2 is implicated in, by any mechanism.

Disease | GeneticClinVar

16 pathogenic / likely-pathogenic of 443 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.04
gnomAD pLI
0
gnomAD missense Z
0.8
DepMap mean gene effect
-0.25
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GFM2 as an antibody target. Whether an autoantibody or antibody against GFM2 could matter depends on whether native GFM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GFM2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label GFM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/GFM2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...